News | News By Subject | News by Disease News By Date | Search News

ALS (Lou Gehrig's disease) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Mitsubishi Tanabe Wins FDA Approval for Radicava, the First New ALS Drug in 22 Years     5/8/2017
Comeback Kid Cytokinetics (CYTK) Pockets $95 Million Upfront in R&D Deal With Astellas (ALPMY), Needs Results for More     7/27/2016
Iron Horse Therapeutics Launched By Avalon Ventures and GlaxoSmithKline (GSK)     11/10/2015
Biogen (BIIB), the ALS Association and Columbia University Medical Center to Map ALS With Ice Bucket Cash     8/18/2015
How Cytokinetics (CYTK) Will Be Getting Some of That Ice Bucket Challenge Cash     7/15/2015
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation     4/22/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS     3/24/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Despite Conflicting Data, Cytokinetics, Inc. (CYTK) Plans To Take ALS Drug Into Late Stage Study     10/21/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy     10/8/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Poaches Renowned Neurologist From Novartis AG (NVS) To Lead ALS Innovation Hub     8/27/2014
Bay Area's Cytokinetics, Inc. (CYTK) Plummets As ALS Drug Fails Phase 2B Study; Stock Down -64.67% At Market Close (April 25, 2014)     4/28/2014
BrainStorm Cell Therapeutics Inc. Says Stem Cells Helped 75-Year Old Patient With ALS And MG     1/7/2014

News from Around the Web
ALS Patients Communicate for First Time in Years With New Device, PLoS Biology Reveals     2/1/2017
One Gene Predicts Rapid ALS Progression 80 Percent of the Time, Methodist Neurological Institute Study     12/10/2012
Stem Cell Model Offers Clues to Cause of Inherited ALS, University of California, San Diego (UCSD) Study     6/22/2011
Ring Finger Length Linked to ALS, King's College London Study Suggests     5/10/2011
Vitamin E Users Show Lower ALS Risk, Harvard University Study     3/17/2011
Cigarette Smoking May Increase Risk of Muscle-Wasting Disease, Harvard School of Public Health Study     2/15/2011
Blue-green Algae Tested for Treating ALS, University of South Florida Study     12/22/2010
Genetic Variations Linked to ALS Risk, University Of Montreal Study     8/31/2010
Brain Trauma Can Mimic Lou Gehrig's Disease, Veterans Affairs Medical Center and Boston University School of Medicine Study     8/18/2010
Cleveland Clinic Researcher Finds Treatment Eases Involuntary Laughing, Crying Tied to Alzheimer's, MS     4/16/2010
Lithium Shows No Benefit in ALS, Massachusetts General Hospital Study     4/6/2010
Compound Shows Potential For Slowing Progression Of Lou Gehrig's Disease, University of Rochester Medical Center Study     10/20/2009
Novel Human Stem Cell-based Model Of Amyotrophic Lateral Sclerosis Opens Doors For Rapid Drug Screening, Salk Institute for Biological Studies Study     12/5/2008
Neurons Derived From Embryonic Stem Cells Restore Muscle Function After Injury, Dalhousie University Study     11/21/2008
University of Rochester Gene Find Sheds Light On Motor Neuron Diseases Like ALS     10/27/2008

Press Releases
FDA Grants Fast Track Designation To Flex Pharma (FLKS)’s FLX-787 For The Treatment Of Severe Muscle Cramps Associated With ALS     7/25/2017
BrainStorm Cell Announces Agreement With University of California, Irvine Medical Center To Participate In Phase III Trial Of NurOwn In ALS     7/25/2017
BrainStorm Cell Awarded $16 Million Non-Dilutive Grant From CIRM In Support Of Phase III Clinical Trial Of NurOwn In ALS     7/21/2017
BrainStorm Cell Announces Agreements With Massachusetts General Hospital And California Pacific Medical Center To Participate In Phase III Trial Of NurOwn In ALS     7/18/2017
Neuraltus Pharmaceuticals, Inc. Announces Completion Of Enrollment In Confirmatory Phase II Study Of NP001 In ALS Patients With Systemic Inflammation     7/12/2017
Worldwide Clinical Trials Selected By BrainStorm Cell As CRO For Phase III NurOwn Trial In ALS     7/5/2017
MT Pharma America Enrolls More Than 700 Sites Of Care In Newly Created National Infusion Center Directory For ALS Patients     7/5/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients     6/21/2017
ProMis Neurosciences Identifies Novel Therapeutic Epitope Target For ALS And Dementia     5/31/2017
CRISPR (CRSP) And Collaborators At The University of Florida Awarded Target ALS Grant To Develop CRISPR/Cas9-Based Approaches For ALS     5/16/2017
French Regulators Order AB Science (AB.PA) To Temporarily Suspend Work On Phase III ALS Trial     5/12/2017
MediciNova, Inc. Announces Exploratory Interim Clinical Outcomes Data From Clinical Trial Of MN-166 (Ibudilast) In ALS Presented At The American Academy of Neurology 69th Annual Meeting In Boston     4/26/2017
Neuraltus Pharmaceuticals, Inc. Release: Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients With High Serum C-Reactive Protein (CRP) Levels May Respond To Immune Regulators Like NP001     4/4/2017
Neuraltus Pharmaceuticals, Inc. Provides Enrollment Update On Confirmatory Phase II Study Of NP001 In ALS     2/9/2017
Barrow Neurological Institute Identifies New Genes Responsible For ALS Using IBM Watson Health     12/15/2016

//-->